Uni-Bio Launches Oral Type 2 Diabetes Drug in China

Uni-Bio Science Group has launched Bokangtai, its oral treatment for Type 2 diabetes, in Fujian province. In 2015, Uni-Bio acquired China rights to Bokangtai, a member of the glinides class of diabetes treatments, from Jiangsu Hansoh Pharma. Uni-Bio has also submitted tenders for Bokangtai in Shanghai, Chongqing, Guangdong and Sichuan, with plans to market Bokangtai in at least 10 provinces by the end of 2017. The drug was included in the 2017 National Reimbursement Drug List. Uni-Bio's R&D operation is located in Dongguan, China. More details.... Stock Symbol: (HK: 690) Share this with colleagues: // //